- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 71 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 359
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Arsenic trioxide, Bortezomib, Melphalan, Autologous hematopoietic stem cell transplantation
- Drug · Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan, Granulocyte-colony stimulating factor
- Procedure · Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
- Interventions
- Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 30 more
- Conditions
- Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
- Procedure · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, peripheral blood stem cell transplantation, iodine I 131 tositumomab, laboratory biomarker analysis, flow cytometry, polymerase chain reaction
- Drug · Procedure · Radiation + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
- Biological · Procedure · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2038
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Interventions
- busulfan, etoposide, aldesleukin, peripheral blood stem cell transplantation
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- GM-K562 vaccine, stem cell transplantation
- Biological · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, tositumomab and iodine I 131 tositumomab
- Drug · Procedure · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer
- Interventions
- COVID-19 Vaccination
- Biological
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
- Interventions
- denintuzumab mafodotin, rituximab, ifosfamide, carboplatin, etoposide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Duarte, California • San Diego, California + 24 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Interventions
- GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
- Biological · Procedure · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- Vorinostat, Gemcitabine, Busulfan, Melphalan, Stem Cell Infusion, Rituximab, G-CSF, Palifermin, Dexamethasone acetate
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Fractionated Stem Cell Infusions
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Rochester, Minnesota • St Louis, Missouri
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Blinatumomab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan, Peripheral blood draws
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- melphalan, amifostine trihydrate, peripheral blood stem cell transplantation, fluorescence in situ hybridization, bone marrow ablation with stem cell support
- Drug · Procedure · Genetic
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Rochester, New York • Seattle, Washington